Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Perioperative Durvalumab-Based Regimen Receives European Approval for Resectable NSCLC

April 4th 2025

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy

April 4th 2025

The European Commission approved trastuzumab deruxtecan for HR-positive, HER2-low or -ultralow metastatic breast cancer after at least 1 endocrine therapy.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer

April 3rd 2025

Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.

Survey Identifies Factors Most Important to Fellows When Selecting a Career Path

April 3rd 2025

A cross-sectional study reveals insights on factors hematology and oncology fellows weigh when selecting a career path after fellowship.

Inotuzumab Ozogamicin–Based Bridging Therapy Boosts Obe-Cel Outcomes in B-Cell ALL

April 1st 2025

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

Donor-Derived CAR T-Cell Therapy Yields High CR Rate With Limited OS in T-Cell Lymphoma After Allo-HSCT Relapse

April 1st 2025

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

AFM28 Shows Preliminary Activity in CD123+ Relapsed/Refractory AML

April 1st 2025

Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.

Orca-T Stands Out From CD34 Grafts, Showing Lower Rates of EBV, CMV Reactivation in Hematologic Malignancies

March 31st 2025

Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.

Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma

March 31st 2025

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

Ivonescimab Shows Significant PFS Improvement Over Pembrolizumab in PD-L1+ NSCLC

March 31st 2025

Xiuning Le, MD, PhD, discusses data from the HARMONi-2 trial of ivonescimab vs pembrolizumab in PD-L1–positive NSCLC.

The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective

March 31st 2025

Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.

Neoadjuvant Pembrolizumab Is Safe and Effective in Resectable Stage III/IV Melanoma

March 30th 2025

Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.

CHMP Recommends Approval of Subcutaneous Nivolumab in Multiple Solid Tumors

March 28th 2025

Meta: The CHMP has recommended the European approval of subcutaneous nivolumab in solid tumors.

Second- and Third-Generation TKI Combo Therapies Are at the Forefront of Frontline Ph+ ALL Investigations

March 28th 2025

Gregory Roloff, MD, highlights ongoing frontline TKI research in Ph-positive ALL and why he uses a newer-generation TKI over imatinib.

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

March 27th 2025

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas

March 27th 2025

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer

March 27th 2025

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Itolizumab Misses Primary End Point in Acute GVHD but Shows Meaningful Improvements in Other Areas

March 27th 2025

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too

March 26th 2025

Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.